Literature DB >> 20466273

Cytomegalovirus in hematopoietic stem cell transplant recipients.

Per Ljungman1, Morgan Hakki, Michael Boeckh.   

Abstract

This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20466273     DOI： 10.1016/j.idc.2010.01.008

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  55 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study.

Authors:  Francesco Marchesi; Fulvia Pimpinelli; Svitlana Gumenyuk; Daniela Renzi; Francesca Palombi; Francesco Pisani; Atelda Romano; Antonio Spadea; Elena Papa; Marco Canfora; Fabrizio Ensoli; Andrea Mengarelli
Journal:  World J Transplant       Date:  2015-09-24

3.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  Cytomegalovirus DNA quantification using an automated platform for nucleic acid extraction and real-time PCR assay setup.

Authors:  Michael Forman; Andy Wilson; Alexandra Valsamakis
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

5.  Construction and Evaluation of Cytomegalovirus DNA Quantification System with Real-Time Detection Polymerase Chain Reaction.

Authors:  Yuki Hatayama; Yuki Hashimoto; Ayako Hara; Toru Motokura
Journal:  Yonago Acta Med       Date:  2016-09-12       Impact factor: 1.641

6.  Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

Authors:  Dirk Kropeit; Jürgen Scheuenpflug; Katharina Erb-Zohar; Atef Halabi; Hans-Peter Stobernack; Ellen G J Hulskotte; Arne van Schanke; Holger Zimmermann; Helga Rübsamen-Schaeff
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

7.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

8.  Repression of eEF2K transcription by NF-κB tunes translation elongation to inflammation and dsDNA-sensing.

Authors:  Christopher Bianco; Letitia Thompson; Ian Mohr
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

9.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

10.  Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.

Authors:  Dirk Kropeit; David McCormick; Katharina Erb-Zohar; Valentin S Moiseev; Zhanna D Kobalava; Hans-Peter Stobernack; Holger Zimmermann; Helga Rübsamen-Schaeff
Journal:  Br J Clin Pharmacol       Date:  2017-08-27       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.